RELAPSED PERIPHERAL T-CELL LYMPHOMA
Clinical trials for RELAPSED PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo offers hope for Hard-to-Treat blood cancer
Disease control Recruiting nowThis study tests whether combining two drugs, pembrolizumab and olaparib, can shrink tumors or slow the growth of peripheral T-cell lymphoma (PTCL) that has returned or not responded to prior therapy. About 24 adults will receive the drugs in 3-week cycles for up to 2 years. The …
Matched conditions: RELAPSED PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated May 15, 2026 12:00 UTC
-
Cancer-Killing virus trial opens for tough lymphomas
Disease control Recruiting nowThis early-stage trial tests a specially modified virus (VSV-hIFNβ-NIS) combined with two immunotherapy drugs (ipilimumab and cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells while leaving healthy cells alone, and the i…
Matched conditions: RELAPSED PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:06 UTC